Michal S.
- Country
- Poland
- Department
- N/A
Research Overview
- Long-term Safety and Efficacy of Abrocitinib in Moderate to Severe Atopic Dermatitis: A Phase 3 Multicenter Extension Study
- Efficacy and Safety Evaluation of Vibozilimod in Moderate to Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial
- Efficacy and Safety Evaluation of Vibozilimod in Moderate to Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 38 of 201 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating severe dermatological conditions, with particular emphasis on atopic dermatitis and plaque psoriasis.
- Moderate to severe atopic dermatitis management
- Plaque psoriasis treatment
- Chronic skin condition therapies
Their research focuses on innovative therapeutic approaches for persistent skin conditions requiring long-term management.
Novel Therapeutics
The investigator evaluates novel therapeutic agents including abrocitinib and SCD-044 for dermatological applications.
- Emerging treatment modalities
- Long-term therapeutic safety
- Combined treatment approaches
Their work encompasses both systemic treatments and combination therapies with topical medications.
Clinical Assessment
The investigator utilizes standardized assessment tools including EASI and PASI scoring systems to evaluate treatment efficacy.
- Disease severity measurement
- Treatment response monitoring
- Long-term efficacy assessment
Their expertise includes systematic evaluation of therapeutic outcomes in chronic skin conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.